Similarly, the phase 2 ATLANTIC trial evaluating the use of durvalumab after ≥2 lines of therapy in those with EGFR-mutant NSCLC, demonstrated that patients with PD-L1 ≥25% had improved RR (12% vs. 4%) and OS (13.3 vs. 9.9 months) compared to those with PD-L1 <25% [109,110]. The gene discussed is EGFR; the disease is non-small cell lung carcinoma.